BofA cuts CNA Financial stock price target on lower earnings outlook

BofA Securities cut CNA Financial’s price target to $42 from $43 and kept an Underperform rating, citing a 13% reduction in its 2026 EPS estimate after the company’s first-quarter 2026 miss and weaker net written premium growth expectations. The stock trades at $43.51, just above its 52-week low of $43.29, and the revised valuation uses an 80% multiple of the large-cap peer group year-ahead P/E of 10.3x. The article also notes CNA’s 8.16% dividend yield and cites a lower 2028 EPS estimate as part of the downgrade rationale.

Analysis

CNA looks like a classic “cheap for a reason” insurer where the market is underestimating how quickly underwriting slippage compounds into multiple compression. The bigger issue is not the one-step target cut; it is that lower premium growth and higher loss assumptions usually force a longer de-rating window than earnings revisions alone imply, because the market stops paying up for capital return durability when the core book weakens. With the stock already near its lows, the path of least resistance remains lower unless management can re-accelerate growth or prove the loss ratio is a one-off, not a trend.

The second-order dynamic is relative: if CNA struggles to defend margins while peers maintain pricing power, capital will likely rotate toward higher-quality P&C names with cleaner combined ratio trajectories and better reserve credibility. That makes CNA vulnerable not just on absolute earnings, but on a factor basis versus other financials that can still support buybacks and dividend growth. The elevated yield can cushion downside, but in weak underwriting cycles high yield often becomes a value trap because the market questions the sustainability of the payout before it questions the headline multiple.

Loews is a quieter signal than CNA but still relevant: the market may reward the parent’s diversification while giving little credit to incremental earnings variability in the insurance complex. If CNA’s reset is read as evidence of broader reserving pressure, Loews’ valuation could look more exposed than the headline results suggest, especially if investors start discounting the quality of capital upstream from subsidiaries. That creates a medium-term overhang rather than a near-term blowup: expect the debate to shift over the next 1-2 quarters from reported EPS to reserve adequacy and capital deployment discipline.

The contrarian case is that the selloff may already reflect a lot of bad underwriting news, and if rates stay elevated, the investment income tailwind can partially offset weaker core underwriting into 2027. That makes the name interesting only if you believe the miss was mostly cyclical rather than structural. If management stabilizes guidance, the stock can mean-revert quickly because sentiment is already fragile and positioning likely light, but absent that, downside rerating risk still dominates.

Key Decisions for Investors

• Short CNA on any bounce back toward the low-$44s; tactical 4-8 week trade with downside toward the low-$40s if guidance remains pressured. Risk/reward is favorable because the stock has little near-term support beyond the dividend yield.
• Pair trade: long higher-quality P&C insurer vs short CNA for 1-2 quarters. Use a cleaner underwriter with stable reserve trends as the long leg; the trade monetizes relative multiple compression if CNA’s loss assumptions keep rising.
• For dividend-focused exposure, avoid adding CNA until there is evidence of loss-ratio stabilization; if holding for yield, sell covered calls 1-2 months out to offset downside while preserving income.
• Watch Loews as a secondary short/hedge candidate only if CNA weakness broadens into the insurance complex; use it as a slower-moving expression on capital allocation and reserve-quality skepticism over the next 1-3 months.
• If CNA can reclaim and hold above the prior 52-week low for multiple sessions with no further estimate cuts, cover shorts quickly; that would signal the market is treating the reset as fully priced and could trigger a technical squeeze.